Wallace Still Sees Opportunity for Intersect, Others in Medtech
George Wallace says his Intersect incubator created 13 companies over 20 years, and exited eight of them.
That’s a pretty good batting average.
“Not bad, some of those exits were better than others,” he says.
But innovators like Wallace continue to innovate, not only with technology but also with finding new ways to create meaningful Medtech companies.
For example, Wallace says Intersect anticipates spending a lot of time in the vascular space. He adds that Intersect is in the process of rolling up “several” companies in that sector. “It’s a pretty comprehensive job and that is going to take over the bulk of our activities over the next two years,” he says.
He’s also learning new ways to raise capital. Micro Therapeutics Inc., for example, raised capital from many different sources including public offering and venture capital.
Now, Wallace says, he’s looking at corporates, OUS investors, and other new sources. Listen to this interview to learn where he’s finding success.
What are the challenges to finding capital from alternative sources? Wallace notes that each investor presents their own unique perspectives and questions.
“I’ve always looked at each individual investor as their own entity,” he says. “Each VC has their own criteria of why they are going to make an investment and why they’re not going to make an investment.”
Learn more about George Wallace here.